Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Bayer
Scott D Solomon; John J V McMurray; Muthiah Vaduganathan; Brian Claggett; Pardeep S Jhund; Akshay S Desai; Alasdair D Henderson; Carolyn S P Lam; Bertram Pitt; Michele Senni; Sanjiv J Shah; Adriaan A Voors; Faiez Zannad; Imran Zainal Abidin; Marco Antonio Alcocer-Gamba; John J Atherton; Johann Bauersachs; Ma Chang-Sheng; Chern-En Chiang; Ovidiu Chioncel; Vijay Chopra; Josep Comin-Colet; Gerasimos Filippatos; Cândida Fonseca; Grzegorz Gajos; Sorel Goland; Eva Goncalvesova; Seokmin Kang; Tzvetana Katova; Mikhail N Kosiborod; Gustavs Latkovskis; Alex Pui-Wai Lee; Gerard C M Linssen; Guillermo Llamas-Esperón; Vyacheslav Mareev; Felipe A Martinez; Vojtěch Melenovský; Béla Merkely; Savina Nodari; Mark C Petrie; Clara Inés Saldarriaga; Jose Francisco Kerr Saraiva; Naoki Sato; Morten Schou; Kavita Sharma; Richard Troughton; Jacob A Udell; Heikki Ukkonen; Orly Vardeny; Subodh Verma; Dirk von Lewinski; Leonid Voronkov; Mehmet Birhan Yilmaz; Shelley Zieroth; James Lay-Flurrie; Ilse van Gameren; Flaviana Amarante; Peter Kolkhof; Prabhakar Viswanathan; FINEARTS-HF Committees and Investigators